Drugs / CAFELKIBART
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT06821503 | Apr 2025 → Dec 2027 expected | malignant pancreatic neoplasm | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06825494 | Apr 2025 → Mar 2026 overdue | neoplasm | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05518045 | Aug 2022 → Mar 2026 overdue | neoplastic disease or syndrome | LaNova Medicines Limited | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05255484 | May 2022 → Oct 2023 | neoplasm | LaNova Medicines Limited | Terminated | No outcome recorded |
| Phase 1/2 | NCT05199753 | Mar 2022 → Dec 2024 | neoplasm | LaNova Medicines Limited | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06873854 | Mar 2025 → Jan 2028 expected | neoplastic disease or syndrome | LaNova Medicines Limited | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06620822 | Sep 2024 → Sep 2026 expected | non-small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06387628 | Jul 2024 → Apr 2026 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06479759 | Jan 2024 → Jun 2025 | non-small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07362186 | Apr 2026 → Aug 2028 expected | gastric adenocarcinoma | LaNova Medicines Limited | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAFELKIBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068098 ↗ |
| Known as | LM-108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06821503 ↗ |
| Known as | LM-108 injection | “LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites.” NCT06825494 ↗ |
| Action | Deplete | “specifically removing tumor-infiltrating regulatory T cells (Treg)” NCT06620822 ↗ |
| Modality | Monoclonal antibody | “Anti-CCR8 Monoclonal Antibody” NCT05518045 ↗ |
| Route | Intravenous | “Administered intravenously” NCT05199753 ↗ |
| Target | CCR8 | “Anti-CCR8 Monoclonal Antibody” NCT05518045 ↗ |